FTSE 100 Rises as lower Oil Prices Lift Market Sentiment

FTSE 100

Market Snapshot

  • FTSE 100: around 10,080, up roughly 1.1%
  • GBP/USD: 1.3396
  • GBP/EUR: about 1.1555
  • Brent crude: around $100.25 per barrel
  • Gold: about $4,582 per troy ounce
  • UK 10-year gilt yield: around 4.78%

The FTSE 100 moved higher on Wednesday as easing oil prices helped improve market sentiment after the previous session’s geopolitical pressure. The index rose by around 1.1%, with investors responding positively to signs of reduced immediate tension in global energy markets and a modest pullback in bond yields.

What’s driving markets today

  1. Brent crude has fallen back towards $100 a barrel, easing some inflation concerns and supporting equity sentiment.
  2. Hopes around possible US-Iran talks have encouraged a relief rally across European markets.
  3. Lower gilt yields have reduced some of the pressure on equity valuations compared with the previous session.
  4. Gold remains elevated, showing that investors are still maintaining a degree of caution despite the market rebound.

FTSE 100 performance breakdown

The FTSE 100 is being supported by an improvement in broader risk appetite as oil prices retreat from recent highs. That has helped reduce some of the immediate inflation pressure that weighed on sentiment earlier in the week. At the same time, the decline in gilt yields has offered some relief for valuations, particularly after markets had become more concerned about the outlook for interest rates.

Even so, the broader backdrop remains fragile. Gold’s continued strength suggests investors are not fully convinced that recent geopolitical risks have passed, which may limit the scope for a sustained rally unless sentiment improves further.

Top Risers

Endeavour Mining rose 4.70% to 4,322.00p, making it the leading gainer in the FTSE 100.
Croda International gained 4.12% to 2,856.00p.
ICG advanced 4.04% to 1,547.00p.
Barratt Redrow rose 4.03% to 273.60p.
Smiths Group gained 3.82% to 2,340.00p.
Anglo American added 3.70% to 3,167.00p.

Top Fallers

Experian fell 2.03% to 2,514.00p, making it the weakest performer among the leading fallers listed.
BT Group declined 1.65% to 203.20p.
RELX slipped 0.99% to 2,406.00p.
Shell eased 0.98% to 3,426.00p.
Pearson fell 0.90% to 944.00p.
Admiral Group dropped 0.51% to 3,140.00p.

Sector Overview

The market tone has improved as lower oil prices reduce pressure on inflation expectations, helping support equities more broadly. Sectors that had been under pressure from rising energy costs and higher yields have seen some relief, while the FTSE 100’s international exposure continues to provide support when global sentiment stabilises. This remains a macro-led move rather than one driven by stock-specific news.

Macro sensitivity

  • The FTSE 100 remains highly sensitive to moves in oil and other major commodities.
  • Lower gilt yields can improve the outlook for equity valuations, particularly when market sentiment is already recovering.
  • Elevated gold prices suggest that defensive positioning remains in place beneath the market rebound.

Risks to watch

  • Any renewed rise in oil prices could quickly bring inflation concerns back into focus.
  • Geopolitical tensions remain a key source of volatility for global markets.
  • If gilt yields move higher again, pressure on valuations could return.
  • A further move higher in gold may signal a more defensive market tone than equity indices currently suggest.

Outlook

Investors are likely to remain focused on whether the recent pullback in oil prices continues and whether geopolitical tensions ease further. The FTSE 100’s near-term direction is likely to depend on whether markets see this as the start of a broader stabilisation in risk sentiment or merely a short-term rebound after recent volatility. Bond yields and commodity prices are likely to remain central to that judgement.

Investor Takeaway

The FTSE 100 is recovering as lower oil prices and easing yields improve sentiment, but the move is still being driven by macro conditions rather than company-specific developments. Investors should watch whether that improvement in sentiment proves durable over the coming sessions. If you found this article helpful use the button below to add us to your preferred sources.

Share on:

Oxford Biomedica reports 9% revenue growth as new client wins accelerate

Oxford Biomedica reported H1 2026 revenue of £79.8 million, up 9% year on year, alongside record new client wins and improved adjusted EBITDA. The company reiterated its FY 2026 guidance and said its Durham, North Carolina GMP manufacturing facility is now operational.

Target Healthcare REIT delivers 12.0% total accounting return as NTA rises 6.4%

Target Healthcare REIT reported its strongest annual financial performance since IPO, with EPRA NTA per share up 6.4%, adjusted earnings per share rising 7.6% and the fully covered annual dividend increasing 2.5%. The portfolio was valued at £924.1 million, with like-for-like rental growth of 3.7%

Rentokil Initial to sell SOLitude Lake Management to Bain Capital for $230m

Rentokil Initial has agreed to sell SOLitude Lake Management and its Vertex Aquatic Solutions division to Bain Capital for $230 million, generating estimated net cash proceeds of around $180 million. The transaction is expected to complete in early Q4 2026, subject to regulatory clearance.

Smiths Group reports FY2026 revenue growth and margin expansion

Smiths Group reported 1.2% organic revenue growth for FY2026, with headline operating margin rising to 20.6%. The company completed major portfolio disposals, acquired DRC Heat Transfer and expects around 4% organic revenue growth in FY2027.

Kingfisher raises full-year guidance after H1 profit growth

Kingfisher reported a 9.9% rise in adjusted pre-tax profit to £404m for the six months ended 31 July 2026, supported by higher gross margins and cost control. The group upgraded its full-year profit and free cash flow guidance.

AstraZeneca’s Klygefa recommended for EU approval in generalised myasthenia gravis

The EMA’s CHMP has recommended Klygefa (gefurulimab) for approval as an add-on treatment for adults with AChR antibody-positive generalised myasthenia gravis, based on Phase III PREVAIL trial results.

North Atlantic Smaller Companies NAV rises 7.7% in first half

North Atlantic Smaller Companies Investment Trust reported a 7.7% rise in NAV per share to 598.1p for the six months ended 31 July 2026, while its share price increased 18.1%. The trust also bought back 5.3 million shares during the period.

Rightmove appoints Rosemary Leith and David Thomas to Board

Rightmove has appointed Rosemary Leith as Senior Independent Director and David Thomas as an Independent Non-Executive Director, strengthening the Board’s technology, governance and property sector expertise.

Search

Search